Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes

被引：3
|
作者：
Smits, M. M. [1 ]
Tonneijck, L. [1 ]
Muskiet, M. H. A. [1 ]
Diamant, M. [1 ]
Kramer, M. H. H. [1 ]
Cahen, D. L. [2 ]
van Raalte, D. H. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Diabet Ctr, Dept Internal Med, Amsterdam, Netherlands
[2] Erasmus Univ, Dept Gastroenterol & Hepatol, Med Ctr, Rotterdam, Netherlands
来源：
DIABETIC MEDICINE | 2017年 / 34卷 / 04期
关键词：
SECRETION; LIPASE;
D O I：
10.1111/dme.13160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [21] The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
    Paul, Sanjoy K.
    Klein, Kerenaftali
    Maggs, David
    Best, Jennie H.
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [22] Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
    Claus, Thomas H.
    Pan, Clark Q.
    Buxton, Joanne M.
    Yang, Ling
    Reynolds, Jennifer C.
    Barucci, Nicole
    Burns, Michael
    Ortiz, Astrid A.
    Roczniak, Steve
    Livingston, James N.
    Clairmont, Kevin B.
    Whelan, James P.
    JOURNAL OF ENDOCRINOLOGY, 2007, 192 (02) : 371 - 380
  • [23] Exenatide at mealtimes in type 1 diabetes-no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
    Doggrell, Sheila A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [24] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805
  • [25] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [26] TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE DECREASES SYSTOLIC BLOOD PRESSURE IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS
    Bulum, T.
    Blaslov, K.
    Prkacin, I.
    Zibar, K.
    Duvnjak, L.
    JOURNAL OF HYPERTENSION, 2015, 33 : E300 - E300
  • [27] Glucagon-Like Peptide-1 and Diabetes
    Monami, Matteo
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [28] Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial
    Smits, M. M.
    Tonneijck, L.
    Muskiet, M. H. A.
    Kramer, M. H. H.
    Diamant, M.
    Pieters-van den Bos, I. C.
    van Raalte, D. H.
    Cahen, D. L.
    DIABETES OBESITY & METABOLISM, 2016, 18 (03): : 281 - 288
  • [29] Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome
    Kunkel, D.
    Basseri, B.
    Low, K.
    Lezcano, S.
    Soffer, E. E.
    Conklin, J. L.
    Mathur, R.
    Pimentel, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 (08): : 739 - E328
  • [30] Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
    Ishoy, Pelle L.
    Knop, Filip K.
    Vilsboll, Tina
    Glenthoj, Birte Y.
    Ebdrup, Bjorn H.
    AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (06): : 681 - 682
12345